Trials employing bintrafusp alfa, a first-in-class bifunctional fusion protein designed to block TGF-β and PD-L1, were evaluated in two randomized phase II studies in lung cancer and one in biliary tract cancer. Here, TGFB1 is linked to lung cancer.